Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Lkb1: An Emerging Therapeutic Target for Cardiovascular Diseases Publisher Pubmed



Molaei A1 ; Molaei E2 ; Sadeghnia H3, 4 ; Hayes AW5 ; Karimi G6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Tehran University of Medical Sciences, Iran
  3. 3. Pharmacological Research Center of Medicinal Plants, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  4. 4. Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  5. 5. University of South Florida College of Public Health, Tampa, FL, United States
  6. 6. Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. Department of Pharmacodynamics and Toxicology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Life Sciences Published:2022


Abstract

Cardiovascular diseases (CVDs) are currently the most common cause of morbidity and mortality worldwide. Experimental studies suggest that liver kinase B1 (LKB1) plays an important role in the heart. Several studies have shown that cardiomyocyte-specific LKB1 deletion leads to hypertrophic cardiomyopathy, left ventricular contractile dysfunction, and an increased risk of atrial fibrillation. In addition, the cardioprotective effects of several medicines and natural compounds, including metformin, empagliflozin, bexarotene, and resveratrol, have been reported to be associated with LKB1 activity. LKB1 limits the size of the damaged myocardial area by modifying cellular metabolism, enhancing the antioxidant system, suppressing hypertrophic signals, and inducing mild autophagy, which are all primarily mediated by the AMP-activated protein kinase (AMPK) energy sensor. LKB1 also improves myocardial efficiency by modulating the function of contractile proteins, regulating the expression of electrical channels, and increasing vascular dilatation. Considering these properties, stimulation of LKB1 signaling offers a promising approach in the prevention and treatment of heart diseases. © 2022 Elsevier Inc.
Related Docs
View other Related Docs
1. Target Sestrin2 to Rescue the Damaged Organ: Mechanistic Insight Into Its Function, Oxidative Medicine and Cellular Longevity (2021)
2. Sestrin2 in Cancer: A Foe or a Friend?, Biomarker Research (2022)
3. Empagliflozin Treatment of Cardiotoxicity: A Comprehensive Review of Clinical, Immunobiological, Neuroimmune, and Therapeutic Implications, Biomedicine and Pharmacotherapy (2023)
4. The C1q/Tnf-Related Proteins (Ctrps) in Pathogenesis of Obesity-Related Metabolic Disorders: Focus on Type 2 Diabetes and Cardiovascular Diseases, Life Sciences (2020)
5. Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-Clinical Therapeutic Approaches, Cardiovascular Toxicology (2022)
6. Lower Circulating Levels of Ctrp12 and Ctrp13 in Polycystic Ovarian Syndrome: Irrespective of Obesity, PLoS ONE (2018)
7. Impact of Polyphenols on Heart Failure and Cardiac Hypertrophy: Clinical Effects and Molecular Mechanisms, Frontiers in Cardiovascular Medicine (2023)
8. Association of Circulating Ctrp9 With Soluble Adhesion Molecules and Inflammatory Markers in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease, PLoS ONE (2018)
Experts (# of related papers)
View all Related Experts
Solaleh Emamgholipour (4)
Karamollah Toolabi (2)
Other Related Docs
9. Sglt2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and Nafld, Endocrinology (United States) (2021)
10. Cardioprotective Effects of Sodium Thiosulfate Against Doxorubicin-Induced Cardiotoxicity in Male Rats, BMC Pharmacology and Toxicology (2022)
11. Circulating Levels of C1q/Tnf-Α‐Related Protein 6 (Ctrp6) in Coronary Artery Disease and Its Correlation With Inflammatory Markers, Journal of Diabetes and Metabolic Disorders (2024)
12. Evidence for the Benefits of Melatonin in Cardiovascular Disease, Frontiers in Cardiovascular Medicine (2022)
13. Ctrp1 in Liver Disease, Advances in Clinical Chemistry (2017)
14. The Gene Expression of Ctrp12 But Not Ctrp13 Is Upregulated in Both Visceral and Subcutaneous Adipose Tissue of Obese Subjects, Diabetes and Metabolic Syndrome: Clinical Research and Reviews (2019)
15. Molecular Genetics of the Pi3k-Akt-Mtor Pathway in Genodermatoses: Diagnostic Implications and Treatment Opportunities, Journal of Investigative Dermatology (2016)
16. Decreased Serum Levels of Ctrp12/Adipolin in Patients With Coronary Artery Disease in Relation to Inflammatory Cytokines and Insulin Resistance, Cytokine (2019)
17. Doxorubicin-Related Cardiotoxicity: Review of Fundamental Pathways of Cardiovascular System Injury, Cardiovascular Pathology (2024)
18. Natural Activators of Adenosine 5′-Monophosphate (Amp)-Activated Protein Kinase (Ampk) and Their Pharmacological Activities, Food and Chemical Toxicology (2018)
19. Increased Mrna Expression of Ctrp3 and Ctrp9 in Adipose Tissue From Obese Women: Is It Linked to Obesity-Related Parameters and Mrna Expression of Inflammatory Cytokines?, Reports of Biochemistry and Molecular Biology (2020)
20. Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?, ACS Pharmacology and Translational Science (2021)
21. Harnessing Polyphenol Power by Targeting Enos for Vascular Diseases, Critical Reviews in Food Science and Nutrition (2023)